Tuesday, July 17, 2018
 
 
Company News: Page (1) of 1 - 07/11/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
BPH is not a risk of prostate cancer, so innovative and safe therapeutic device should be used in the first instance

(July 11, 2018)

Benign prostatic hyperplasia (BPH) and prostate cancer may have same symptoms but BPH is non-life-threatening ageing condition. For this metabolic problem innovative Thermobalancing therapy with Dr Allenís therapeutic device should be administered to men, as the first-line BPH treatment.

Prostate enlargement develops slowly squeezing bladder that leads to annoying lower urinary tract symptoms (LUTS), such as frequent or urgent need to urinate; increased frequency of urination at night; difficulty with starting urination; weak urine stream and others. Therefore, the cessation of the growth of the prostate gland is the main goal, when men choose the treatment option for BPH. Please watch an explanation why Thermobalancing therapy should be used in the first instance at the following video: https://youtu.be/Fr3oFP8p3ks.

Standard BPH drugs Alfa-blockers, Proscar (Finasteride) or Avodart (Dutsteride) do not treat a prostate but may develop serious side effects. Alfa-blockers are responsible for sexual dysfunction, whereas Proscar and Avodart - for impotence, increase blood sugar and blood lipids, so can cause diabetes and a heart attack. Therefore, BPH surgeries are often prescribed. After even minimal invasive surgeries men might urinary tract infection, dry orgasm; erectile dysfunction; heavy bleeding; difficulty holding urine; low sodium in the blood and need for re-treatment.



Dr Allenís device relieves LUTS due to BPH as it terminates prostate enlargement. A clinical trial has confirmed that Dr Allenís device decreases the size of enlarged prostate, which reduces the urinary symptoms and improves the quality of life. Dr Simon Allen explains that Thermobalancing therapy treats the cause of enlarged prostate by improving blood circulation in the prostate gland.

ďBy the age of 60, 50% of men will suffer lower LUTS. Today, as life expectancy increases, the administration to men with BPH drugs and risky surgery should be a last resort,Ē says Dr Allen.

Dr. Allen shared his opinion about the results of a clinical trial of Thermobalancing therapy in men with BPH at various international conferences around the world: in Spain, China, Italy, the UK, France and other countries. The outcomes of 10 years empirical evidence and the clinical trial were published in leading medical journals.

Fine Treatment, delivers the device† to all countries across the world within a week, by using Royal Mail tracking service. Men can receive the device and use it at home. Furthermore, Fine Treatment is a UK Department for International Trade (DIT) registered supplier to international buyers:

https://trade.great.gov.uk/suppliers/08994517/fine-treatment-limited/. For over 10 years Dr. Allenís Devices have been successfully used by thousands of customers in over 100 countries. Read more at: http://finetreatment.com.

Media Contact
Company Name: Fine Treatment
Contact Person: Dr Simon Allen, MD, PhD, Director of Fine Treatment
Email: Send Email
Phone: +447958878300
Country: United Kingdom
Website: http://finetreatment.com




Page: 1


Related Keywords:Lifestyle,U.S,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Personal Care Home Consultant Lynn Marting Helps Families Find the Right Facility for Aging Loved Ones
  • Global Cosmetic Chemicals Industry
  • HMP's 8th Annual Amputation Prevention Symposium Expected to Draw 800 Clinicians to Chicago to Join the CLI Revolution
  • Progressive Care Inc. Announces Month-End Sales Figures Showing Increase in Year-Over-Year Prescriptions Filled in June 2018
  • Mount Sinai Health System and Arena Address AI-Driven Hiring for Healthcare at Leading Industry Conference

    Cancer
  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  • Corporate Whistleblower Center Now Targets Hospice Providers Ripping Off Medicare And Urges Their Employees with Proof a of Wrongdoing to Call About Rewards -- Don't Get Mad, Get Even
  • Corporate Whistleblower Center Now Targets Hospice Providers Ripping Off Medicare And Urges Their Employees with Proof a of Wrongdoing to Call About Rewards -- Don't Get Mad, Get Even
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines